Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$30.60 USD
+0.53 (1.76%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $30.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SUPN 30.60 +0.53(1.76%)
Will SUPN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SUPN
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
Other News for SUPN
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Notable Two Hundred Day Moving Average Cross - SUPN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
Supernus Provides Regulatory Update for SPN-830
Supernus stock slides as FDA rejects Parkinson's disease infusion device